In Vitro: Travoprost has sub-micromolar affinity for the DP, EP1, EP3, EP4, IP, and TP receptors.
In Vivo: Travoprost produces a lower incidence of ocular irritation than PGF20 isopropyl ester at a dose of 1 μg in the New Zealand albino (NZA) rabbit. Topical ocular application of Travoprost produces a marked miotic effect in cats following doses of 0.01, 0.03 and 0.1 μg. In the ocular hypertensive monkey, b.i.d. application of 0.1 and 0.3 μg of travoprost afforded peak reduction in intraocular pressure (IOP) of 22.7% and 28.6%, respectively. Topical application of travoprost was well tolerated in rabbits, cats and monkeys, causing no ocular irritation or discomfort at doses up to 1 μg.